CHARACTERIZING ASSOCIATION BETWEEN EARLY ENDPOINTS AND OVERALL SURVIVAL AND EVENT-FREE SURVIVAL IN RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
Source: RTI International
August 16, 2021 – August 15, 2024
HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFRmutated Non-Small Cell Lung Cancer (NSCLC)
Source: Daiichi Sankyo, Inc
May 20, 2021 – May 19, 2024
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Source: Mirati Therapeutics, Inc.
April 06, 2021 – April 05, 2024
CHIO3 Trial: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Source: Alliance Foundation Trials, LLC.
March 25, 2021 – March 24, 2024
Phase 1 Study of Entinostat in Combination with Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer
Source: Johns Hopkins University, The
March 15, 2021 – March 14, 2024
Experimental Therapeutics Clinical Trials Network (ETCTN)
Source: Johns Hopkins University, The
May 01, 2020 – February 28, 2023
A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFRmutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor ECTN 9903
Source: Johns Hopkins University, The
February 01, 2017 – February 28, 2023
A Phase 2 Study of MEDI4736(durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Source: Johns Hopkins University, The
September 15, 2017 – February 28, 2023
A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non¿Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Source: Takeda Pharmaceuticals
February 04, 2020 – February 03, 2023
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-small Cell Lung Cancer or Urothelial Cancer
Source: Jounce Therapeutics, Inc.
October 16, 2019 – October 15, 2022
A phase II study of Carboplatin plus Pemetrexed plus Atezolizumab plus Bevacizumab in chemotherapy and immunotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
Source: Hoosier Cancer Research Network, Inc.
September 10, 2019 – September 09, 2022
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer
Source: Hoosier Cancer Research Network, Inc.
August 19, 2019 – August 18, 2022
MD-INMD-HO A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Source: Merck Sharp & Dohme Corp.
May 18, 2015 – May 31, 2022
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Source: ECOG-ACRIN Cancer Research Group
June 11, 2018 – May 05, 2022
MD-INMD-HO Gentzler Merck MK 3475-671-0013
Source: Merck Sharp & Dohme Corp.
April 19, 2018 – April 18, 2022
MD-INMD-HO A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During of After Receiving at Least One Prior Systemic Regimen
Source: Bristol-Myers Squibb Company
October 13, 2014 – March 30, 2022
MD-INMD-HO Phase I/II study of carboplatin/nab-paclitaxel and pembrolizumab for patients with advanced non-small cell lung cancer (NSCLC)
Source: Hoosier Cancer Research Network, Inc.
February 16, 2016 – February 15, 2022
MD-INMD-HO - Gentzler - Takeda AP32788-15-101
Source: PRA Health Sciences
January 16, 2019 – January 15, 2022
Real-time Monitoring and Modeling of Symptoms and Adverse Events in Lung Cancer Patients Receiving Oral Targeted Therapies for Tumors with EGFR mutations or ALK Rearrangements
Source: Pfizer Inc.
December 20, 2019 – December 31, 2021
MD-INMD-HO - Gentzler - Helsinn ANAM 17-20
Source: Psi Pharma Support America Inc.
April 15, 2019 – June 29, 2021
A phase II trial of concurrent chemoradiation with consollidation Pembrolizumab for the treatment of Inoperable or unresectable stage III non-small cell lung cancer (NSCLC): LUN14-179
Source: Allakos, Inc.
July 01, 2016 – June 10, 2021
LUNGMAP A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
Source: ECOG-ACRIN Cancer Research Group
March 01, 2019 – May 21, 2021
MD-CANC ECOG-ACRIN Master
Source: ECOG-ACRIN Cancer Research Group
May 01, 2016 – April 30, 2021
MD-INMD-HO Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Source: ECOG-ACRIN Cancer Research Group
January 14, 2015 – March 05, 2021
NCTN High Performance Site Initiative
Source: PPD Development, Inc.
November 01, 2017 – December 31, 2020
S1900A: A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH- OR BRCA-POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Source: ECOG-ACRIN Cancer Research Group
March 01, 2019 – October 30, 2020
